New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

OCREVUS (ocrelizumab) injection, for intravenous use

This specialty medication is manufactured abroad and is not registered or commercially marketed for retail sale in India. Access in India may require specific regulatory approvals or personal import permits as prescribed by relevant authorities. Under Named Patient Supply, SDP can serve you. To know the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.

Facts of Ocrevus (ocrelizumab)

OCREVUSTM (ocrelizumab) injection, for intravenous use
Initial U.S. Approval: 2017
Injection: 300 mg/10 mL (30 mg/mL) in a single-dose vial.
Company: Genentech

South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Ocrevus (ocrelizumab) ” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Ocrevus (ocrelizumab) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

Description

What Ocrevus is?

OCREVUS is a prescription medicine used to treat:

  • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
  • Primary progressive MS, in adults.

What ocrelizumab is?

Ocrelizumab, sold under the brand name Ocrevus, is a pharmaceutical drug for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody.[3] It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug.[4] Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds

Related Products